Skip to main content

Peer Review reports

From: Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report

Original Submission
6 Jul 2021 Submitted Original manuscript
19 Jul 2021 Reviewed Reviewer Report - Mohamad K. Abou Chaar
3 Aug 2021 Reviewed Reviewer Report - luigi cavanna
4 Aug 2021 Reviewed Reviewer Report - Teodora Alexa - Stratulat
12 Sep 2021 Reviewed Reviewer Report - Rahul Arora
21 Oct 2021 Author responded Author comments - Zsófia Küronya
Resubmission - Version 2
21 Oct 2021 Submitted Manuscript version 2
22 Nov 2021 Reviewed Reviewer Report - Binny Khandakar
5 Feb 2022 Reviewed Reviewer Report - Rahul Arora
1 Mar 2022 Author responded Author comments - Zsófia Küronya
Resubmission - Version 3
1 Mar 2022 Submitted Manuscript version 3
3 May 2022 Reviewed Reviewer Report - Krishna Sharan
7 May 2022 Reviewed Reviewer Report - Ho Gwo Fuang
7 Jun 2022 Author responded Author comments - Zsófia Küronya
Resubmission - Version 4
7 Jun 2022 Submitted Manuscript version 4
1 Jul 2022 Reviewed Reviewer Report - Krishna Sharan
3 Oct 2022 Reviewed Reviewer Report - Tibor Fülöp
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
3 Oct 2022 Editorially accepted
31 Oct 2022 Article published 10.1186/s13256-022-03634-x

You can find further information about peer review here.

Back to article page